ENLIVEX THERAPEUTICS LTD (ENLV) Stock News

USA - Nasdaq - NASDAQ:ENLV - IL0011319527 - Common Stock

0.9 USD

-0.08 (-8.16%)

Last: 11/26/2025, 8:00:01 PM

0.9128 USD

+0.01 (+1.42%)

After Hours: 11/26/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ENLV Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Chartmill - Mentions: SUPX CMCT CAPR AEHL ...

News Image

Which stocks are experiencing notable movement on Monday?

3 days ago - By: Chartmill - Mentions: PLUG NVDA OPEN AEHL ...

News Image

These stocks are making the most noise in today's session.

20 hours ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement

20 hours ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement

2 days ago - By: Enlivex Therapeutics Ltd

Enlivex anuncia una colocación privada de $212,000,000 para iniciar la primera estrategia de tesorería de activos digitales basada en mercados de predicción en el mundo, mediante la acumulación del token RAIN, y el nombramiento de Matteo Renzi, ex Primer

2 days ago - By: Enlivex Therapeutics Ltd

Enlivex mengumumkan Penempatan Persendirian bernilai AS$212,000,000 untuk Memulakan Strategi Perbendaharaan Aset Digital Pasaran Ramalan Pertama di Dunia, melalui Pengumpulan token RAIN, serta Pelantikan Matteo Renzi, Bekas Perdana Menteri Itali, ke dalam

2 days ago - By: Enlivex Therapeutics Ltd

Enlivex Anuncia Colocação Privada de US $212.000.000 para Início da Primeira Estratégia de Previsão de Mercados de Tesouro de Ativos Digitais do Mundo, via Acumulação de tokens RAIN, e a Nomeação de Matteo Renzi, Ex-Primeiro-Ministro da Itália, para seu

2 days ago - By: Enlivex Therapeutics Ltd

エンライベックス (Enlivex)、RAINトークンの蓄積を通じた世界初の予測市場デジタル資産財務戦略を開始するための2億1,200万ドル (約333億円) の私募および、イタリア元首相マッテオ・レンツィ (Matteo Renzi) の取締役任命を発表

2 days ago - By: Enlivex Therapeutics Ltd

Enlivex 宣佈透過 2.12 億美元私人配售，透過累積 RAIN 代幣啟動全球首個預測市場數碼資產儲備策略，並任命意大利前總理 Matteo Renzi 加入董事局

2 days ago - By: Enlivex Therapeutics Ltd

Enlivex annonce un placement privé de 212 000 000 $ pour lancer la première stratégie au monde de trésorerie d’actifs numériques sur les marchés prédictifs, via l’accumulation de jetons RAIN, et la nomination de Matteo Renzi, ancien Premier ministre

2 days ago - By: Enlivex Therapeutics Ltd

Enlivex, RAIN 토큰 축적 통한 세계 최초 예측시장 디지털 자산 재무전략 위해 2억 1200만 달러 사모투자 및 Matteo Renzi 이탈리아 전 총리 이사진 합류 발표

3 days ago - By: Chartmill - Mentions: SUPX CMCT CAPR MBRX ...

News Image

Top movers in Monday's session

3 days ago - By: Chartmill - Mentions: BFLY INSP SUPX TE ...

News Image

The market is filled with gapping stocks in Monday's session.

3 days ago - By: Enlivex Therapeutics Ltd.

Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

3 days ago - By: Stocktwits - Mentions: RAIN

ENLV Stock Surges After Pivot To Crypto-Backed Treasury, Names Former Italian PM To Board

3 days ago - By: Chartmill - Mentions: NVO INSP VIV OSCR ...

News Image

Wondering what's happening in today's pre-market session?

3 days ago - By: Enlivex Therapeutics Ltd

Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

3 days ago - By: Enlivex Therapeutics Ltd

Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

3 days ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

3 days ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

a month ago - By: Enlivex Therapeutics Ltd

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

a month ago - By: Enlivex Therapeutics Ltd

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

2 months ago - By: ACCESS Newswire - Mentions: LTRN

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

2 months ago - By: Enlivex Therapeutics Ltd

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

2 months ago - By: Enlivex Therapeutics Ltd

D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program

2 months ago - By: ACCESS Newswire - Mentions: SXTP

Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

3 months ago - By: Enlivex Therapeutics Ltd

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

3 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

3 months ago - By: Benzinga - Mentions: TNXP SNGX USBC BNR ...

12 Health Care Stocks Moving In Monday's Intraday Session

3 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

3 months ago - By: Enlivex Therapeutics Ltd

Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

3 months ago - By: Enlivex Therapeutics Ltd

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

3 months ago - By: Enlivex Therapeutics Ltd

Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

4 months ago - By: Enlivex Therapeutics Ltd

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

4 months ago - By: Enlivex Therapeutics Ltd

Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

6 months ago - By: ACCESS Newswire - Mentions: FMST

Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV